Stocktoria
Kiniksa Pharmaceuticals International, plc KNSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-05-24
Kiniksa Pharmaceuticals International, plc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% |
| FCF margin | 20.1% | 6.0% | 4.9% | 2.6% | -328.7% |
| Return on assets | 7.7% | -7.4% | 2.7% | 39.9% | -67.8% |
| Return on equity | 10.4% | -9.9% | 3.2% | 46.3% | -85.3% |
| Current ratio | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 |
| Revenue growth | 60.1% | 56.6% | 22.7% | 471.2% | — |
Source: SEC EDGAR filings · CIK 0001730430 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.